NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that it has formed a strategic partnership with Ascendas Genomics to develop molecular diagnostics in China.

Under the agreement, Ascendas will develop and commercialize molecular diagnostic systems and assays using microfluidic technologies included in Fluidigm's Biomark HD and Juno systems.

Fluidigm's platforms enable scalable and automated workflows for quantitative PCR, gene expression, copy number variation analysis, and next-generation sequencing library preparation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.